Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24127287 | 0.86 | KMT2A (0.40) | — | |
| SCHEMBL25884693 | 0.85 | L3MBTL3 (0.40) | ACKR3 | |
| SCHEMBL25953626 | 0.84 | ALDH1A1 (0.34) | ACKR3 | |
| SCHEMBL23325468 | 0.83 | KMT2A (0.33) | ACKR3 | |
| SCHEMBL23342023 | 0.82 | DPP4 (0.33) | ACKR3 | |
| SCHEMBL23325467 | 0.81 | MEN1 (0.40) | ACKR3 | |
| SCHEMBL25900393 | 0.78 | ACKR3 (0.33) | ACKR3 | |
| SCHEMBL25900409 | 0.77 | — | — | |
| SCHEMBL25884689 | 0.77 | ACKR3 (0.30) | ACKR3 | |
| SCHEMBL20063333 | 0.76 | SMN1; SMN2 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-11566007-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210130303-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| US-20210130369-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566007-B2 | Ras inhibitors | KRAS, NRAS, HRAS | ACKR3 3902/4885 |
| US-20230234929-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ACKR3 3902/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | ACKR3 4556/4885 |
| US-20210130303-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ACKR3 3902/4885 |
| US-20230374035-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ACKR3 3902/4885 |
| US-20210130369-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ACKR3 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.